DGAP-News: Sucampo Names Peter Greenleaf Chief Executive Officer

DGAP-News: Sucampo Pharmaceuticals, Inc. /
Sucampo Names Peter Greenleaf Chief Executive Officer

10.02.2014 / 22:02

---------------------------------------------------------------------

BETHESDA, Md., 2014-02-10 22:02 CET (GLOBE NEWSWIRE) --
Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ('Sucampo') today announced that
Peter Greenleaf will join Sucampo as Chief Executive Officer ('CEO') and as a
member of the Board of Directors ('Board') on March 3, 2014. Mr. Greenleaf, 43,
brings to Sucampo more than 20 years of experience in commercialization and
drug development in the biopharmaceutical industry. 

A photo accompanying this release is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=23524 

Ryuji Ueno, M.D., Ph.D., Ph.D. will step down as CEO, Chairman of the Board,
and member of the Board when Mr. Greenleaf joins Sucampo. In addition, Dr. Ueno
will step down as Chief Scientific Officer on March 31, 2014.  As Co-Founder,
Chairman Emeritus, and Scientific Advisor, Dr. Ueno will provide consulting
services to ensure a smooth transition and advise Sucampo on the development of
its pipeline and other strategic activities, through a one-year, renewable
contract. 

In addition, Dan Getman, Ph.D. has been named Chairman of the Board, effective
March 3, 2014. Dr. Getman has been a Director of Sucampo since 2011 and is the
current Chairman of Sucampo's Science and Technology Committee, as well as
Chairman and/or member of other Board committees. 

'Peter's expertise in growing biopharmaceutical companies, including experience
leading a gastroenterology business, will be a valuable addition to Sucampo.
The Board is confident that under his leadership Sucampo's legacy of growth
will be accelerated,' said Dr. Getman. 'Peter brings the right mix of
commercial, strategic planning, and product development expertise that we
believe will enhance the value of Sucampo's proprietary prostone technology and
its delivery to patients and healthcare providers around the world. On behalf
of the entire Board, I also want to thank Dr. Ueno for his visionary leadership
and the strong scientific foundation he established for Sucampo. His
breakthrough discovery of the therapeutic potential of prostones led to the
development and approval of two products, and it established Sucampo as a
global biopharmaceutical company whose medicines have benefited millions of
patients across three continents.' 

Dr. Ueno stated, 'I believe that Peter brings the right experience to lead
Sucampo during this pivotal time. I look forward to supporting him and the
management team as they expand the potential of Sucampo's prostone technology,
which has resulted in two approved products marketed globally.' 

Mr. Greenleaf is the President, CEO and Board member of Histogenics, a
regenerative medicine company. Prior to his leadership of Histogenics, Mr.
Greenleaf served as President of MedImmune, the global biologics arm of
AstraZeneca, where he was instrumental in driving the expansion of MedImmune's
pipeline into over 120 clinical and pre-clinical programs and the
commercialization of its marketed products. Mr. Greenleaf also served as
President of MedImmune Ventures, a wholly owned venture capital fund within the
AstraZeneca Group, where he led investment in emerging biopharmaceutical,
medical device, and diagnostic companies. 

'I am excited to join Sucampo at this critical time in the company's growth,'
said Mr. Greenleaf. 'Sucampo has evolved into a global biopharmaceutical
company with products approved on three continents. And, with its rich
pipeline, the company is poised to harness the significant potential of its
prostone technology via additional therapeutic areas that can address a greater
number of unmet patient needs. I look forward to working with Dr. Ueno, the
management team and the Board of Directors to ensure that Sucampo's ongoing
commitment to deliver patient, physician and shareholder value continues to
expand and grow.' 

Prior to serving as President of MedImmune, Mr. Greenleaf was the Chief
Commercial Officer of the company, responsible for its commercial, corporate
development and strategy functions. Mr. Greenleaf has also held senior
commercial roles at Centocor, leading the company's gastroenterology division,
and has additional experience at Boehringer Mannheim and Hallmark Cards, Inc. 

Mr. Greenleaf currently chairs the Maryland Venture Fund Authority, whose
vision is to oversee implementation of InvestMaryland, a public-private
partnership to spur venture capital investment in the state. Mr. Greenleaf's
previous Board appointments include the Biotechnology Industry Organization
('BIO'); the University of Maryland Baltimore Foundation, Inc.; Rib-X
Pharmaceuticals; LigoCyte Pharmaceuticals; and Corridor Pharmaceuticals. He
received a Master of Business Administration degree from St. Joseph's
University and a Bachelor of Science degree from Western Connecticut State
University. 

Dr. Getman was a Vice President of global research and development at Pfizer
and Director of the company's St. Louis Laboratories, which played a key role
in the company's biotherapeutics, inflammation research, and indications
discovery. Dr. Getman has also held senior positions at Pharmacia, Searle, and
Monsanto in research and development and medicinal chemistry, and he is the
former Chairman of the Missouri Biotechnology Association (MOBIO). Dr. Getman
earned a Ph.D. in Organic Chemistry from the University of Minnesota, in
Minneapolis, and a Bachelor of Science degree in Chemistry from SUNY Buffalo. 

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company focused on
innovative research, discovery, development and commercialization of
proprietary drugs based on prostones.  The therapeutic potential of prostones
was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., co-founder of Sucampo. 
Prostones, naturally occurring fatty acid metabolites that have emerged as
promising compounds with unique physiological activities, can be targeted for
the treatment of unmet or underserved medical needs.  Sucampo has two marketed
products - AMITIZA(r) and RESCULA(r) - and a pipeline of prostone-based product
candidates in clinical development. A global company, Sucampo is headquartered
in Bethesda, Maryland, and has operations in Japan, the United Kingdom and
Switzerland. For more information, please visit www.sucampo.com. 

The Sucampo logo and the tagline, The Science of Innovation, are registered
trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
RESCULA is a registered trademark of R-Tech Ueno, Ltd, and has been licensed to
Sucampo AG. 

Sucampo Forward-Looking Statement

This press release contains 'forward-looking statements' as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks and
uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of pharmaceutical
industry regulation and health care legislation; Sucampo's ability to
accurately predict future market conditions; dependence on the effectiveness of
Sucampo's patents and other protections for innovative products; the risk of
new and changing regulation and health policies in the U.S. and internationally
and the exposure to litigation and/or regulatory actions. No forward-looking
statement can be guaranteed and actual results may differ materially from those
projected. Sucampo undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events, or otherwise. Forward-looking statements in this presentation should be
evaluated together with the many uncertainties that affect Sucampo's business,
particularly those mentioned in the risk factors and cautionary statements in
Sucampo's most recent Form 8-K and 10-K, which Sucampo incorporates by
reference. 

Follow us on Twitter (@Sucampo_Pharma). Follow us on Linkedin (Sucampo
Pharmaceuticals). 

Twitter     LinkedIn

The photo is also available at Newscom, www.newscom.com, and via AP
PhotoExpress. 


         CONTACT:  Silvia Taylor
         Senior Vice President, Investor Relations, PR,
         and Corporate Communications
         1-240-223-3718
         staylor@sucampo.com
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

10.02.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                        
Company:     Sucampo Pharmaceuticals, Inc.  
 
 
             United States                  
ISIN:        US8649091068                   
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
251966 10.02.2014